News India Network

Future: Sun Pharma Is Expecting To Reward Investors Again After A 1,150% Dividend, With Q3 In Focus: Should You Purchase This Stock?

<p>1. To review and accept the company’s unaudited standalone and consolidated financial results for the quarter and nine months that ended on December 31, 2023.</p>
<p><img decoding=”async” class=”alignnone wp-image-361992″ src=”” alt=” future sun pharma is expecting to reward investors again after a 1150 dividend wit” width=”1076″ height=”606″ title=”Future: Sun Pharma Is Expecting To Reward Investors Again After A 1,150% Dividend, With Q3 In Focus: Should You Purchase This Stock? 9″ srcset=” 600w,×220.jpg 390w,×85.jpg 150w” sizes=”(max-width: 1076px) 100vw, 1076px” /></p>
<p>2. To take into account and accept the interim dividend declaration for the 2023–2024 fiscal year.”</p>
<p><strong>Sun Pharma Dividend</strong><br />
The record date for the next dividend has already been set by the corporation. It said, “The Interim Dividend, if declared, shall be paid to the equity shareholders of the Company whose names appear on the Register of Members as of February 9, 2024, which is the Record Date fixed for this purpose.”</p>
<p><strong>Thus. On February 9, Sun Pharma shares will also go ex-dividend.</strong></p>
<p>Sun Pharma paid a whopping 1150% dividend last year, or Rs 11.5 per share. Sun Pharma’s dividend yield, as of the current market price, is 0.87%.</p>
<p>Sun Pharma’s share is now trading at Rs 1,325.85 on the BSE. Sun Pharma’s shares rose to a new 52-week high on Saturday, January 20, during the normal trading session that preceded the Ayodhya Ram Mandir event. Its market capitalization is at Rs 3,18,108.37 crore. Sun Pharma’s shares shot up 26.55% on the market in a year.</p>
<p>In Q3, what can we anticipate from Sun Pharma?<br />
In the preview report, Prabhudas Lilladher “Over the last few years SUNP dependency on US generics has reduced and company’s growth is more functional on US specialty, RoW, and domestic pharma business that continues to show strong growth visibility.”</p>
<p>“Specialty product portfolio and domestic business to deliver growth YoY,” the email from PL said. The domestic formulating industry will expand by 11% annually. Overhead and margin projections will be important metrics to watch.”</p>
<p>PL anticipates revenues of Rs 12,405.1 crore for the quarter, up 1.7% QoQ and 10.4% YoY. At Rs 3,354.5 crore, EBITDA has increased by 4.4% QoQ and 11.6% YoY. In Q3FY24, adjusted PAT increased by 3.6% QoQ and 13.6% YoY to Rs 2,460 crore.</p>
<p>In a report, JM Financial said, “We anticipate robust specialty sales of USD 268 million and around 10% domestic growth. We use gRevlimid to bake USD 20 million.” The firm has suggested purchasing Sun Pharma with a 12-month target price of Rs 1,440.</p>
<p>Elara Capital said in its most recent research note, dated January 18, “We retain our FY24E-26E core profit projections. At 31.5x core FY25E EPS, SUNP is traded. Although the recent surge in the stock price may have made valuations seem a little excessive, we anticipate that they will hold given the likelihood of further earnings improvements from the US generics upcycle and the operational leverage in the specialty sector.”</p>
<p>“We raise our TP from Rs 1,246 to Rs 1,484, which is 31x FY26E core EPS plus cash per share,” Elara’s letter said. The main risks to our call and forecasts include a delayed US launch of deuruxolitinib and a slower rate of recovery in US generics profitability.”</p>

Related posts

Mcap of the top four most valuable companies rises by Rs 65,671 crore, with Reliance emerging as the greatest beneficiary

Air India Express: Summer Schedule: Over 360 Daily Flights, 20% Increase in International Services

Discover C Vijayakumar, India’s highest-paid CEO

Report: Roark Capital Is Considering Purchasing Sandwich Chain Subway for $9.6 billion.

Amazing Technology: Tim Cook, CEO of Apple, Explains Why the Vision Pro Headset Is About Rs. 3 Lakh

Cambridge Youth Are Inspired by Billionaire Anil Agarwal’s Journey From Scrap To Success